

**Biocon Biologics Limited**

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,  
Semicon Park Electronic City, Phase - II,  
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** [contact@bioconbiologics.com](mailto:contact@bioconbiologics.com)[www.bioconbiologics.com](http://www.bioconbiologics.com)

February 18, 2025

**Singapore Exchange Securities Trading Limited**

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

**Subject: Company Statement**

Please find enclosed the company statement titled **"European Commission Approves Biocon Biologics' Ustekinumab Biosimilar"**.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

**For Biocon Biologics Limited**

**Akhilesh  
Nand** Digitally signed by  
Akhilesh Nand  
Date: 2025.02.18  
09:29:15 +05'30'

**Akhilesh Nand****Company Secretary**

Membership No. ACS 13669

Address: Biocon House, Semicon Park

Tower 3, Electronic City Phase 2, Hosur Road

Bengaluru, Karnataka

Encl: as above

## NOTIFICATION TO STOCK EXCHANGE

### COMPANY STATEMENT

## European Commission Approves Biocon Biologics' Ustekinumab Biosimilar

***Bengaluru, Karnataka, India, February 18, 2025***

**Biocon Biologics Ltd (BBL)**, a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the European Commission (EC) granted marketing authorisation in the European Union (EU) for YESINTEK®, a biosimilar of Ustekinumab.

YESINTEK®, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease. Clinical data from the trial program showed that Ustekinumab biosimilar has comparable safety and efficacy to the originator product.

The marketing authorisation approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued on December 14, 2024.

*– Company Spokesperson*

*YESINTEK is a registered trademark of Biocon Biologics Limited.*

*All other trademarks, registered or unregistered, are the property of their respective owners.*

*For more information: [seema.ahuja@biocon.com](mailto:seema.ahuja@biocon.com)*